Eutylone (also known as β-keto-1,3-benzodioxolyl-N-ethylbutanamine, bk-EBDB, and N-ethylbutylone) is a stimulant and empathogenic compound developed in the 1960s,[3][4] which is classified as a designer drug.[5] It was first reported to the EMCDDA in 2014 and became widespread internationally in 2019-2020 following bans on the related compound ephylone.[6][7][8][9] It is not a natural, but a synthetic cathinone.[9] In 2021, eutylone was the most common cathinone identified by the Drug Enforcement Administration in the United States.[10]
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C13H17NO3 |
Molar mass | 235.283 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Sweden's public health agency suggested classifying eutylone as a hazardous substance, on September 25, 2019.[11]
In the United States Eutylone is considered a schedule 1 controlled substance as a positional isomer of Pentylone.[12][13]